Sanofi
company
Investments
Number of Investments
Number of Lead Investments
25
14
Sanofi has made 25 investments. Their most recent investment was on
Nov 23, 2022, when Livmed's, Inc raised
| Date | Company Name | Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|---|
| Nov 23, 2022 | Livmed's | Seed | — | Delivery Service | Yes |
| Aug 4, 2022 | Innovent Biologics | Post-IPO Equity | — | Biopharma | Yes |
| Jul 12, 2022 | Areteia Therapeutics | Series A | — | Biotechnology | — |
| Jan 10, 2022 | Exscientia | Post-IPO Equity | — | Artificial Intelligence | Yes |
| Nov 18, 2021 | Owkin | Corporate Round | — | Artificial Intelligence | Yes |
| Nov 8, 2021 | Gyroscope Therapeutics | Corporate Round | — | Biotechnology | Yes |
| Feb 16, 2021 | Novadiscovery | Series A | — | Artificial Intelligence | Yes |
| Oct 3, 2019 | Icosavax | Series A | — | Biotechnology | — |
| Sep 5, 2019 | Veralox Therapeutics | Seed | — | Biotechnology | Yes |
| Feb 5, 2019 | Aetion | Series B | — | Analytics | — |
| Jan 4, 2019 | BioNTech | Corporate Round | — | Biopharma | Yes |
| Oct 25, 2018 | Enable Injections | Series B | — | Health Care | Yes |
| Oct 2, 2018 | Eden Biologics | Post-IPO Equity | — | Biopharma | Yes |
| Sep 5, 2018 | Fulcrum Therapeutics | Series B | — | Biotechnology | — |
| Sep 28, 2017 | Thermalin | Series A | — | Biotechnology | Yes |
| Dec 5, 2016 | Eden Biologics | Private Equity（PE） | — | Biopharma | — |
| Sep 12, 2016 | Onduo | Seed | — | Fitness | — |
| Oct 15, 2014 | Portal Instruments | Series A | — | Health Care | Yes |
| Aug 22, 2014 | MyoKardia | Series Unknown | — | Biopharma | — |
| Feb 7, 2012 | Melinta Therapeutics | Post-IPO Equity | — | Biotechnology | Yes |
| Jan 11, 2012 | Warp Drive Bio | Private Equity（PE） | — | Biotechnology | — |
| Jun 1, 2011 | Esperance Pharmaceuticals | Series B | — | Biotechnology | Yes |
| Apr 14, 2011 | KAHR medical | Series Unknown | — | Biotechnology | — |
| Oct 28, 2010 | Regulus Therapeutics | Funding Round | — | Biotechnology | — |
| Oct 19, 2005 | Nereus Pharmaceuticals | Series D | — | Biotechnology | — |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
